2024
The Role of Social Determinants in Diagnosis Timing for Fetal Care Center-Eligible Conditions: A Scoping Review
Wilpers A, Eichhorn B, Batten J, Francis K, Powne A, Jumale S, Hansen K, Kohari K, Lorch S. The Role of Social Determinants in Diagnosis Timing for Fetal Care Center-Eligible Conditions: A Scoping Review. Diagnostics 2024, 14: 1503. PMID: 39061640, PMCID: PMC11276164, DOI: 10.3390/diagnostics14141503.Peer-Reviewed Original ResearchSocial determinants of healthIndicators of social determinants of healthCongenital heart diseaseSocial determinantsFetal care centersIndividual-level social determinants of healthSocial determinants of health categoriesSocial determinants of health indicatorsSocial determinants of health frameworkDeterminants of healthFetal conditionStructural-level factorsHealthy peopleScoping reviewSocioeconomic statusPostnatal planMaternal ageCare centerIndividual studiesFetal diagnosisPrenatal treatmentHealthyHeart diseaseAnalyzed dataTimely identificationRate of clinically significant red blood cell antibody seroconversion in pregnancy
Ding J, Abels E, Jacobs J, Culhane J, Lundsberg L, Partridge C, Denoble A, Kohari K. Rate of clinically significant red blood cell antibody seroconversion in pregnancy. The Journal Of Maternal-Fetal & Neonatal Medicine 2024, 37: 2419370. PMID: 39462637, DOI: 10.1080/14767058.2024.2419370.Peer-Reviewed Original ResearchConceptsNeonatal intensive care unitAdvanced maternal ageAssociated with seroconversionClinically significant antibodiesAntibody screeningNeonatal outcomesIncreasing gravidityAntibody seroconversionInitial hemoglobinMaternal ageSignificant antibodiesAntibody statusNeonatal intensive care unit admissionCohort studyClinically significant RBC antibodiesAnti-CUnexplained fetal lossPositive antibody screenNegative antibody screenCases of stillbirthRetrospective cohort studyIntensive care unitWilcoxon rank-sumMaternal antibody statusPostnatal transfusion
2020
Chapter 12 Prenatal testing
Copel J, Kohari K, Merriam A. Chapter 12 Prenatal testing. 2020, 201-221. DOI: 10.1016/b978-0-12-816561-4.00012-0.ChaptersPrenatal testingMaternal-fetal medicineSecond-trimester screeningFirst-trimester screeningTime of deliveryWhole-exome sequencingChorionic villus samplingCurrent pregnancyCell-free fetal DNA screeningCertain patientsMaternal ageReproductive endocrinologyGenetic testingVillus samplingDNA screeningPatientsObstetricsSitu hybridizationScreeningTest optionsMedical GeneticsRiskGeneticsOptionsPregnancy
2016
Outcome after implementation of a modern management strategy for intrahepatic cholestasis of pregnancy
Kohari KS, Carroll R, Capogna S, Ditchik A, Fox NS, Ferrara LA. Outcome after implementation of a modern management strategy for intrahepatic cholestasis of pregnancy. The Journal Of Maternal-Fetal & Neonatal Medicine 2016, 30: 1342-1346. PMID: 27418248, DOI: 10.1080/14767058.2016.1212833.Peer-Reviewed Original ResearchConceptsNeonatal outcomesIntrahepatic cholestasisBile acidsContinuous fetal heart rate monitoringModern management strategiesGreater maternal ageRetrospective cohort studyFetal heart rate monitoringCesarean delivery rateTotal bile acidsNew management protocolNew cohortNICU admissionGestational diabetesSingleton gestationsCohort studyPatient demographicsPregnancy outcomesInpatient admissionsMaternal ageHeart rate monitoringStillbirth rateWeeksCholestasisOutcomes